Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Andrew Vaillant, Victor Pântea et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 249
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-upCorinne Castelnau, Elyanne Gault, Frédéric Le Gal et al.|Hepatology|2006Cited by 238
Eighth Major Clade for Hepatitis Delta VirusFrédéric Le Gal, Paul Dény, Elyanne Gault et al.|Emerging infectious diseases|2006Cited by 206
Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strainsFrédéric Le Gal, Emmanuel Gordien, Jean–Michel Pawlotsky et al.|Hepatology|2017Cited by 152
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis deltaDominique Roulot, Sophie Hillaire, Ségolène Brichler et al.|Journal of Hepatology|2020Cited by 151